Health Condition 1: L811- Chloasma
Conditions
Interventions
Intervention1: NIL: NIL
Intervention2: Platelet rich plasma(PRP): Ten milliliter of blood is withdrawn from the patient using a vacuum tube containing an anticoagulant (sodium citrate). Double centrif
Sponsors
Department of Dermatology
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with clinical diagnosis of melasma
Exclusion criteria
Exclusion criteria: 1. Patients with known platelet dysfunction syndrome, critical thrombocytopenia ( 2. Patients with local inflammatory skin disorders or active herpes infection at the site of the procedure. 3. Patients with corticosteroid injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks. 4. Patients diagnosed with cancer especially hematopoietic or of bone. 5. Patient with known hypersensitivity to platelet rich plasma or any other form of blood components. 6. Patients with any other facial dermatoses. 7. Patients on anticoagulants, oral contraceptive pills, hormone replacement therapy, NSAIDs, antiepileptic medications, isotretinoin or any other phototoxic medication. 8. Pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage reduction in modified melasma area severity indexTimepoint: Intralesional injection at 1st month 2nd month 3rd month Follow up at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects- Nausea Vomiting Diarrhoea Pain at site Fever Hematoma Erythema Local warmth Bleeding Any other TO LOOK FOR OTHER ADDED BENEFITS OF PRP IF ANY Timepoint: 1st month 2nd month 3rd month 6 th month | — |
Countries
India
Contacts
Public ContactAnkita Tuknayat
Government Medical college and hospital
Outcome results
None listed